NPCE

NeuroPace Inc

7.56

Nov 13 • 3:59 PM ET -4.46 (-37.10%)

7.20

Aftermarket • 7:59 PM ET -0.36 (-4.76%)

Healthcare Medical Devices USA Micro NASD

Today, 2:02 AMNeuroPace misses Q3 estimates, cuts 2026 revenue guidance, and targets 2027 RNS growth re-acceleration

Peers: LIVN MDT CLPT INSP ECOR BWAY BSX STIM NYXH ABT

| Held by: VTI IWM VXF IWO VTWO IWC XHE VTWG GSSC RSSL

Scroll to Statements

Index	RUT
Market Cap	259.49M
Enterprise Value	279.80M
Income	-18.92M
Sales	94.59M
Book/sh	0.33
Cash/sh	1.43
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	209
IPO	Apr 22, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	2.74
P/B	22.65
P/C	5.27
P/FCF	-
EV/EBITDA	-
EV/Sales	2.96
Quick Ratio	4.09
Current Ratio	5.26
Debt/Eq	6.05
LT Debt/Eq	5.85
Option/Short	Yes / Yes

EPS (ttm)	-0.56
EPS next Y	-0.46
EPS next Q	-0.17
EPS this Y	12.50%
EPS next Y	21.00%
EPS next 5Y	15.88%
EPS past 3/5Y	30.02% 8.43%
Sales past 3/5Y	29.99% 19.44%
EPS Y/Y TTM	25.96%
Sales Y/Y TTM	-0.29%
EPS Q/Q	9.00%
Sales Q/Q	-15.54%
Earnings	Nov 12 AMC
EPS/Sales Surpr.	8.09% -14.82%

Insider Own	21.91%
Insider Trans	0.00%
Inst Own	74.53%
Inst Trans	3.09%
ROA	-18.73%
ROE	-126.06%
ROIC	-24.03%
Gross Margin	80.82%
Oper. Margin	-15.39%
Profit Margin	-20.00%
SMA20	-39.69%
SMA50	-42.76%
SMA200	-48.79%
Trades

Shs Outstand	34.43M
Shs Float	26.80M
Short Float	3.20%
Short Ratio	6.66
Short Interest	0.86M
52W High	19.60 -61.43%
52W Low	11.90 -36.47%
Volatility	12.47% 6.92%
ATR (14)	1.11
RSI (14)	20.72
Beta	1.94
Rel Volume	47.41
Avg Volume	128.95K
Volume	6,113,430

Perf Week	-39.52%
Perf Month	-40.85%
Perf Quarter	-47.06%
Perf Half Y	-50.78%
Perf YTD	-51.04%
Perf Year	-40.98%
Perf 3Y	-10.95%
Perf 5Y	-46.00%
Perf 10Y	-
Recom	1.89
Target Price	12.88
Prev Close	12.02
Price	7.56
Change %	-37.10%

Consensus

Buy

Avg. Price Target

$12.88

Implied Upside

+70.4%

Analysts14incl. previous ratings

Rating Distribution10 Buy · 4 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Today	Downgrade	WWells Fargo	Overweight → Equal Weight	$19 → $9	+19.0%
Today	Downgrade	LLeerink	Outperform → Market Perform	$7	-7.4%
Today	Downgrade	JJP Morgan	Overweight → Neutral	$9	+19.0%
Sep 18, 2026	Initiated	KKeyBanc Capital Markets	Overweight	$18	+138.1%
Jul 23, 2026	Initiated	MMizuho	Outperform	$22	+191.0%
May 28, 2025	Initiated	HH.C. Wainwright	Buy	$18	+138.1%
Jan 21, 2025	Initiated	UUBS	Buy	$17	+124.9%
Mar 14, 2024	Upgrade	WWells Fargo	Equal Weight → Overweight	$16 → $20	+164.6%
Jan 30, 2024	Initiated	LLeerink Partners	Outperform	$22	+191.0%
Nov 10, 2023	Initiated	CCantor Fitzgerald	Overweight	$11	+45.5%
Aug 24, 2023	Upgrade	MMorgan Stanley	Underweight → Equal-Weight	$5 → $6	-20.6%
Feb 22, 2023	Initiated	LLake Street	Buy	$10	+32.3%
Apr 06, 2022	Initiated	WWolfe Research	Outperform	$13	+72.0%
Jan 19, 2022	Downgrade	WWells Fargo	Overweight → Equal Weight	$11	+45.5%
Jan 07, 2022	Downgrade	MMorgan Stanley	Equal-Weight → Underweight	$17 → $12	+58.7%
Nov 11, 2021	Downgrade	MMorgan Stanley	Overweight → Equal-Weight
Aug 18, 2021	Initiated	RRobert W. Baird	Outperform	$26	+243.9%
May 17, 2021	Initiated	WWells Fargo	Overweight	$25	+230.7%
May 17, 2021	Initiated	SSVB Leerink	Outperform	$25	+230.7%
May 17, 2021	Initiated	MMorgan Stanley	Overweight	$26	+243.9%

Nov-12-26 06:52PM	NeuroPace Stalls: RNS Growth Collapses To 1% And A Deep Guidance Cut Overshadows Record Margins (Earnings Whispers) -37.10%
04:13PM	NeuroPace Inc.: Q3 Earnings Snapshot (Associated Press)
04:05PM	NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance (Business Wire)
Nov-04-26 06:12PM	NeuroPace Must Show Core RNS Strength Can Carry The Story While IGE Approval Stalls (Earnings Whispers) +8.37%
Oct-29-26 04:05PM	NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026 (Business Wire) -5.46%
05:01PM	Loading…
Sep-01-26 05:01PM	NeuroPace to Participate in 2026 Cantor Global Healthcare Conference (Business Wire)
Aug-31-26 04:05PM	NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference (Business Wire)
Aug-18-26 09:01PM	NeuroPace Inc (NPCE) (Q2 2026) Earnings Call Highlights: Strong RNS Growth and AI Launch Offset ... (GuruFocus.com)
Aug-11-26 04:19PM	NeuroPace Inc.: Q2 Earnings Snapshot (Associated Press)
04:05PM	NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance (Business Wire)
Jul-28-26 04:01PM	NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy (Business Wire) -10.91%
May-29-26 08:05AM	NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting (Business Wire)
08:00AM	NeuroPace Announces FDA Approval of ECoG Assistant, Advancing AI-Driven Epilepsy Care (Business Wire)
May-28-26 11:29AM	NPCE Explains How NeuroPace's RNS System Makes Money (Quartz)
11:29AM	NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care (Quartz)
11:29AM	Loading…
11:29AM	Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift? (Quartz)
May-13-26 01:02AM	NeuroPace Inc (NPCE) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
May-12-26 04:30PM	NeuroPace Inc.: Q1 Earnings Snapshot (Associated Press)
04:05PM	NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance (Business Wire)
May-11-26 11:45AM	NeuroPace (NPCE) Moves 6.3% Higher: Will This Strength Last? (Quartz) -14.60%
09:20AM	NeuroPace Inc (NPCE) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-29-26 04:05PM	NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026 (Business Wire)
Apr-27-26 07:30AM	NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026 (Business Wire)
Apr-10-26 04:05PM	NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-10-26 11:40AM	Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026 (Zacks)
11:39AM	NPCE RNS System Explained: Growth Drivers and Setup for 2026 (Zacks)
11:21AM	NeuroPace's Seizure ID and New Indication Could Expand RNS Demand (Zacks)
Mar-05-26 04:30PM	NeuroPace to Present at the Leerink Global Healthcare Conference (Business Wire)
Mar-04-26 12:01AM	NeuroPace Inc (NPCE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Mar-03-26 06:02PM	NeuroPace Q4 Earnings Call Highlights (MarketBeat)
05:35PM	Loading…
05:35PM	NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:36PM	NeuroPace Inc.: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook (Business Wire)
Mar-02-26 07:19AM	NeuroPace Inc (NPCE) Q4 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-25-26 12:15PM	LivaNova (LIVN) Tops Q4 Earnings and Revenue Estimates (Zacks)
10:00AM	Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-24-26 10:00AM	NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-20-26 04:30PM	NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026 (Business Wire)
Feb-12-26 05:35PM	Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Jan-13-26 07:30AM	NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook (Business Wire)
Dec-31-25 09:00AM	NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-17-25 08:00AM	NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS System Indication for Idiopathic Generalized Epilepsy (Business Wire)
Dec-08-25 08:00AM	NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy (Business Wire)
Dec-02-25 08:01AM	NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting (Business Wire)
Nov-24-25 08:00AM	NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services (Business Wire) +13.31%
Nov-05-25 12:04AM	NeuroPace Inc (NPCE) Q3 2025 Earnings Call Highlights: Record Revenue and Positive EBITDA Milestone (GuruFocus.com) +38.09%
Nov-04-25 06:20PM	NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
05:17PM	NeuroPace Inc.: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance (Business Wire)
Nov-03-25 08:04AM	NeuroPace Inc (NPCE) Q3 2025 Earnings Report Preview: What to Look For (GuruFocus.com) -5.43%
Oct-22-25 08:00AM	NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025 (Business Wire)
Aug-28-25 08:00AM	NeuroPace to Participate in Upcoming Healthcare Conferences (Business Wire)
Aug-13-25 03:13AM	NeuroPace Inc (NPCE) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
Aug-12-25 05:25PM	NeuroPace, Inc. (NPCE) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:35PM	NeuroPace Inc.: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance (GlobeNewswire)
Aug-11-25 09:35AM	Earnings To Watch: NeuroPace Inc (NPCE) Reports Q2 2025 Result (GuruFocus.com)
Aug-07-25 05:40PM	Stereotaxis Inc. (STXS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-06-25 05:45PM	PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-05-25 08:25AM	Orthofix (OFIX) Q2 Earnings and Revenues Beat Estimates (Zacks)
Aug-01-25 07:30AM	NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases (GlobeNewswire) +5.64%
Jul-29-25 04:05PM	NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire)
Jul-15-25 07:40AM	AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Jun-24-25 04:05PM	NeuroPace Announces Strategic CFO Transition (GlobeNewswire)
Jun-17-25 01:35PM	NeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician Survey (Insider Monkey)
Jun-04-25 04:09PM	NeuroPace Secures Up to $75 Million in Debt Financing (GlobeNewswire)
May-29-25 02:48PM	H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating (Insider Monkey) +5.22%
May-28-25 11:50AM	NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial (Zacks)
10:45AM	NeuroPace reports initial one-year outcomes from trial of RNS System (Medical Device Network)
May-27-25 12:48PM	Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data? (Benzinga) -28.39%
08:00AM	NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study (GlobeNewswire)
May-15-25 08:06AM	5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil (Zacks) +9.49%
May-14-25 12:56PM	Q1 2025 Neuropace Inc Earnings Call (Thomson Reuters StreetEvents) +20.46%
03:15AM	NeuroPace Inc (NPCE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
May-13-25 05:25PM	NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:23PM	NeuroPace Inc.: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	NeuroPace Reports First Quarter 2025 Financial Results (GlobeNewswire)
08:50AM	Recent Price Trend in NeuroPace (NPCE) is Your Friend, Here's Why (Zacks)
May-12-25 05:15PM	DaVita HealthCare (DVA) Q1 Earnings and Revenues Beat Estimates (Zacks)
09:33AM	NeuroPace Inc (NPCE) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-09-25 08:20AM	Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 06:15PM	Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-05-25 05:30PM	Tactile Systems Technology (TCMD) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-14-25 04:05PM	NeuroPace Provides Update on Tariff Status (GlobeNewswire)
Apr-08-25 08:00AM	NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting (GlobeNewswire) -9.76%
Apr-03-25 08:00AM	NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting (GlobeNewswire)
Apr-02-25 04:05PM	NeuroPace Announces Refocusing of Product Portfolio (GlobeNewswire)
Mar-26-25 08:00AM	NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-05-25 06:49AM	Q4 2024 Neuropace Inc Earnings Call (Thomson Reuters StreetEvents)
02:09AM	NeuroPace Inc (NPCE) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Mar-04-25 04:24PM	NeuroPace Inc.: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 09:15PM	UPDATE NeuroPace to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire) -8.80%
04:05PM	NeuroPace to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
07:14AM	NeuroPace Inc (NPCE) Q4 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Feb-21-25 05:13AM	NeuroPace (NPCE) Surges 5.8%: Is This an Indication of Further Gains? (Zacks)
Feb-20-25 04:05PM	NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd. (GlobeNewswire) +5.80%
Feb-19-25 04:05PM	NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 (GlobeNewswire)
Feb-18-25 04:05PM	NeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +9.18%
Feb-14-25 08:12AM	NeuroPace Prices $65 Million Offering; Shares Drop in Pre-Market (GuruFocus.com)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Morrell Martha	CHIEF MEDICAL OFFICER	Dec 15 '25	Sale	15.97	25,000	399,250	49,964	Mar 04 04:43 PM
MARTHA J MORRELL	Officer	Dec 15 '25	Proposed Sale	16.19	25,000	404,750		Dec 15 04:26 PM

NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.

CEOMr. Joel D. Becker

Chief Financial OfficerMr. Patrick F. Williams

Chief Medical OfficerDr. Martha J. Morrell M.D.

Chief of Operations & DevelopmentMr. Dylan St. John

Head of Investor RelationsMr. Scott R. Schaper

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

NPCE

NeuroPace Inc

Upgrade your Finviz experience

All the Features.
Half the Price.